Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Ulrich Kilian is active.

Publication


Featured researches published by Ulrich Kilian.


British Journal of Pharmacology | 1995

Dose‐response comparisons of five lung surfactant factor (LSF) preparations in an animal model of adult respiratory distress syndrome (ARDS)

Dietrich Häfner; Rolf Beume; Ulrich Kilian; Georg Krasznai; Burkhard Lachmann

1 We have examined the effects of five different lung surfactant factor (LSF) preparations in the rat lung lavage model. In this model repetitive lung lavage leads to lung injury with some similarities to adult respiratory distress syndrome with poor gas exchange and protein leakage into the alveolar spaces. These pathological sequelae can be reversed by LSF instillation soon after lavage. 2 The tested LSF preparations were: two bovine: Survanta and Alveofact: two synthetic: Exosurf and a protein‐free phospholipid based LSF (PL‐LSF) and one Recombinant LSF at doses of 25, 50 and 100 mg kg−1 body weight and an untreated control group. 3 Tracheotomized rats (10–12 per dose) were pressure‐controlled ventilated (Siemens Servo Ventilator 900C) with 100% oxygen at a respiratory rate of 30 breaths min−1, inspiration expiration ratio of 1: 2, peak inspiratory pressure (PIP) of 28 cmH2O at positive end‐expiratory pressure (PEEP) of 8 cmH2O. Two hours after LSF administration, PEEP and in parallel PIP was reduced from 8 to 6 (1st reduction), from 6 to 3 (2nd reduction) and from 3 to 0 cmH2O (3rd reduction). 4 Partial arterial oxygen pressure (Pao2, mmHg) at 5 min and 120 min after LSF administration and during the 2nd PEEP reduction (Pao2(PEEP23/3)) were used for statistical comparison. All LSF preparations caused a dose‐dependent increase for the Pao2(120′), whereas during the 2nd PEEP reduction only bovine and recombinant LSF exhibited dose‐dependency. Exosurf did not increase Pao2 after administration of the highest dose. At the highest dose Exosurf exerted no further improvement but rather a tendency to relapse. The bovine and the Recombinant LSF are superior to both synthetic LSF preparations. 5 In this animal model and under the described specific ventilatory settings, even between bovine LSF preparations there are detectable differences that are pronounced when compared to synthetic LSF without any surfactant proteins. We conclude that the difference between bovine and synthetic LSF preparations can be overcome by addition of the surfactant protein C.


Archive | 1994

Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors

Hermann Amschler; Dieter Flockerzi; Beate Gutterer; Armin Hatzelmann; Christian Schudt; Rolf Beume; Ulrich Kilian; Horst Wolf


Planta Medica | 1996

Constituents of Veltheimia viridifolia. I. Homoisoflavanones of the bulbs

Gudrun Amschler; August W. Frahm; Armin Hatzelmann; Ulrich Kilian; D. Müller-Doblies; U. Müller-Doblies


Archive | 1990

Arylpyridazines, their preparation, their use and pharmaceuticals containing them

Hermann Amschler; Wolf-Rüdiger Ulrich; Rolf Beume; Klaus Eistetter; Manfrid Eltze; Dieter Flockerzi; Ulrich Kilian; Christian Schudt


Archive | 1999

Benzamides with tetrahydrofuranyloxy substitutents as phosphodiesterase 4 inhibitors

Thomas Bär; Thomas Martin; Wolf-Rüdiger Ulrich; Hermann Amschler; Beate Gutterer; Dieter Flockerzi; Armin Hatzelmann; Hildegard Boss; Rolf Beume; Ulrich Kilian; Hans-Peter Kley


Archive | 1985

Pyridazinones, their preparation and use, medicaments containing pyridazinones

Hermann Amschler; Klaus Eistetter; Manfrid Eltze; Dieter Flockerzi; Ulrich Kilian; Norbert Kolassa; Karl Dr. Sanders; Wolf-Rüdiger Ulrich


Archive | 1991

New sulfonyl compounds

Dieter Flockerzi; Kurt Klemm; Hermann Amschler; Volker Figala; Rolf Beume; Dietrich Häfner; Guido Hanauer; Manfrid Eltze; Christian Schudt; Ulrich Kilian


Archive | 2000

Synergistic combination comprising roflumilast and a PDE-3 inhibitor

Ulrich Kilian


Archive | 1999

Treatment set containing lungsurfactant compositions

Dietrich Häfner; Paul-Georg Germann; Herbert Rupp; Klaus Eistetter; Ulrich Kilian


Archive | 1995

Compositions containing at least one glucocorticoid in combination with a pulmonary surfactant for the treatment of irds and ards

Dietrich Häfner; Paul-Georg Germann; Klaus Eistetter; Ulrich Kilian

Collaboration


Dive into the Ulrich Kilian's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Klaus Eistetter

Massachusetts Institute of Technology

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Kurt Klemm

University of Freiburg

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge